Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 study of remimazolam with sufentanil for adult gastroscopy sedation
ChiCTR2200062381Phase 4Not yet recruiting
- Sponsor
- Zhuji People's Hospital of Zhejiang Province
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam and sufentanil in None, sponsored by Zhuji People's Hospital of Zhejiang Province. Primary endpoint: ED90 of remimazolam combined with sufentanil in adult gastroscopy. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
remimazolamsufentanil
Beyond the preview
Go deeper on ChiCTR2200062381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062381.